Table 4 Estimation of CLN.HCl in their pharmaceutical preparations using the proposed kinetic methods and reference methods:
Formula | Drug | Claim (mg/tab) | Recovery % ± S.D* | Reference method [3] | |
|---|---|---|---|---|---|
Proposed kinetic method | |||||
Fixed time | Initial rate | ||||
Clindo** | CLN | 75 | 99.13% ± 2.07 t = 1.76 F = 2.83 | 98. 97 ± 1.34 t = 1.64 F = 2.87 | 100.16% ± 0.25 t = 1.42 |
150 | 101.12% ± 0.63 t = 2.08 F = 2.45 | 100.83% ± 1.36 t = 1.93 F = 2.39 | 101.16% ± 1.02 t = 1.54 | ||
300 | 100.18% ± 0.99 t = 1.84 F = 2. 13 | 100.89% ± 1.03 t = 2.45 F = 1.98 | 100.75% ± 0.28 t = 1.13 | ||
Fixed time | Initial rate | ||||
Clindamycin Biomed*** | CLN | 75 | 99.19% ± 0.69 t = 0.16 F = 2.39 | 100.15% ± 1.38 t = 1.56 F = 2.18 | 100.53% ± 1.02 t = 0.83 |
150 | 99.25% ± 1.17 t = 1.46 F = 2.37 | 100.25% ± 0.87 t = 2.10 F = 2.67 | 101.19% ± 1.00 t = 0.79 | ||
300 | 100.29% ± 1.19 t = 1.18 F = 2.72 | 101.50% ± 1.05 t = 1.82 F = 2.28 | 100.76% ± 0.89 t = 1.09 | ||